Viral Hepatitis

You have full text access to this OnlineOpen article

High diversity of hepatitis C viral quasispecies is associated with early virological response in patients undergoing antiviral therapy†

  1. Xiaofeng Fan1,2,‡,*,
  2. Qing Mao3,4,
  3. Donghui Zhou1,5,
  4. Yang Lu1,
  5. Jianwei Xing1,
  6. Yanjuan Xu1,
  7. Stuart C. Ray3,
  8. Adrian M. Di Bisceglie1,2,‡,*

Article first published online: 9 SEP 2009

DOI: 10.1002/hep.23290

Issue

Hepatology

Hepatology

Volume 50, Issue 6, pages 1765–1772, December 2009

Additional Information

How to Cite

Fan, X., Mao, Q., Zhou, D., Lu, Y., Xing, J., Xu, Y., Ray, S. C. and Di Bisceglie, A. M. (2009), High diversity of hepatitis C viral quasispecies is associated with early virological response in patients undergoing antiviral therapy. Hepatology, 50: 1765–1772. doi: 10.1002/hep.23290

Author Information

  1. 1

    Division of Gastroenterology and Hepatology, Department of Internal Medicine, St. Louis University School of Medicine, St. Louis, MO

  2. 2

    St. Louis University Liver Center, St. Louis University School of Medicine, St. Louis, MO

  3. 3

    Division of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD

  4. 4

    Department of Infectious Diseases, Southwest Hospital, Third Military Medical University, Chongqing, China

  5. 5

    Department of Infectious Diseases, First Affiliated Hospital of Nanjing Medical University, Nanjing, China

  1. ‡

    fax: (314) 577-8125.

*Division of Gastroenterology and Hepatology, Department of Internal Medicine, St. Louis University School of Medicine, 3635 Vista Avenue, St. Louis, MO 63110

  1. †

    Potential conflict of interest: Dr. Di Bisceglie is a consultant for and received grants from Roche. Drs. Ray and Mao received grants from Roche.

Publication History

  1. Issue published online: 20 NOV 2009
  2. Article first published online: 9 SEP 2009
  3. Accepted manuscript online: 9 SEP 2009 12:00AM EST
  4. Manuscript Accepted: 6 AUG 2009
  5. Manuscript Received: 4 FEB 2009

Funded by

  • Roche, USA
  • NIH. Grant Numbers: R01 DK80711, R21 AI076834

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article with Supporting Information (HTML) Get PDF (294K)

References

  • 1
    National Institutes of Health. NIH Consensus Development Conference Statement: management of hepatitis C. HEPATOLOGY 2002; 36( Suppl 1): S3–S20.
  • 2
    Feld, JJ, Hoofnagle JH. Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature 2005; 436: 967–972.
  • 3
    Wohnsland A, Hofmann WP, Sarrazin C. Viral determinants of resistance to treatment in patients with hepatitis C. Clin Microbiol Rev 2007; 20: 23–38.
  • 4
    Upchurch DA, Shankarappa R, Mullins JI. Position and degree of mismatches and the mobility of DNA heteroduplexes. Nucleic Acids Res 2000; 28: E69.
  • 5
    Di Bisceglie AM, Ghalib RH, Hamzeh FM, Rustgi VK. Early virologic response after peginterferon alpha-2a plus ribavirin or peginterferon alpha-2b plus ribavirin treatment in patients with chronic hepatitis C. J Viral Hepatitis 2007; 14: 721–729.
  • 6
    Higgins DG, Sharp PM. CLUSTAL: a package for performing multiple sequence alignment on a microcomputer. Gene 1988; 73: 237–244.
  • 7
    Hall TA. BioEdit: a user-friendly biological sequence alignment editor and analysis program for Windows 95/98/NT. Nucleic Acids Symp Ser 1999; 41: 95–98.
  • 8
    Clauset A, Shalizi CR, Newman MEJ. Power-law distributions in empirical data. 2007; http://arxiv.org/abs/0706.1062.
  • 9
    Di Bisceglie AM, Fan X, Chambers T, Strinko J. Pharmacokinetics, pharmacodynamics, and hepatitis C viral kinetics during antiviral therapy: the null responder. J Med Virol 2006; 78: 446–451.
  • 10
    Ross RS, Viazov S, Roggendorf M. Genotyping of hepatitis C virus isolates by a new line probe assay using sequence information from both the 5′ untranslated and the core regions. J Virol Methods 2007; 143: 153–160.
  • 11
    Abbate I, Lo Iacono O, Di Stefano R, Cappiello G, Girardi E, Longo R, et al. HVR-1 quasispecies modifications occur early and are correlated to initial but not sustained response in HCV-infected patients treated with pegylated- or standard-interferon and ribavirin. J Hepatol 2004; 40: 831–836.
  • 12
    Shan-Lu Liu SL, Rodrigo AG, Shankarappa R, Learn GH, Hsu L, Davidov O, et al. HIV quasispecies and resampling. Science 1996; 273: 413–417.
  • 13
    Fan X, Solomon H, Poulos JE, Neuschwander-Tetri BA, Di Bisceglie AM. Comparison of genetic heterogeneity of hepatitis C viral RNA in liver tissue and serum. Am J Gastroenterol 1999; 94: 1347–1354.
  • 14
    Fan X, Lyra AC, Tan D, Xu Y, Di Bisceglie AM. Differential amplication of hypervariable region 1 of hepatitis C virus by partially mismatched primers. Biochem Biophys Res Commun 2001; 284: 694–697.
  • 15
    Torres-Puente M, Bracho MA, Jimenez N, Garcia-Robles I, Moya A, Gonzalez-Candelas F. Sampling and repeatability in the evaluation of hepatitis C virus genetic variability. J Gen Virol 1003; 84: 2343–2350.
  • 16
    Ferenci P, Fried M, Shiffman M, Smith C, Marinos G, Gonçales F, et al. Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD)/ribavirin. J Hepatol 2005; 43: 425–433.
  • 17
    Mihm U, Herrmann E, Sarrazin C, Zeuzem S. Review article: predicting response in hepatitis C virus therapy. Aliment Pharm Therap 2006; 23: 1043–1054.
  • 18
    Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958–965.
  • 19
    Shiffman ML, Di Bisceglie AM, Lindsay KL, Morishima C, Wright EC, Everson GT, et al. Peginterferon Alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology 2004; 126: 1015–1023.
  • 20
    Nei M. Phylogenetic analysis in molecular evolutionary genetics. Annu Rev Genet 1996; 30: 371–403.
  • 21
    Mondelli MU, Cerino A, Meola A, Nicosia A. Variability or conservation of hepatitis C virus hypervariable region 1? Implications for immune responses. J Biosci 2003; 28: 305–310.
  • 22
    Mondelli MU, Cerino A, Segagni L, Meola A, Cividini A, Silini E, et al. Hypervariable region 1 of hepatitis C virus: immunological decoy or biologically relevant domain? Antivir Res 2001; 52: 153–159.
  • 23
    Bak P. How Nature Works: The Science of Self-organized Criticality. New York: Springer; 1999: 1–31.
  • 24
    Gonzalez-Peralta RP, Qian K, She JY, Davis GL, Ohno T, Mizokami M, et al. Clinical implications of viral quasispecies heterogeneity in chronic hepatitis C. J Med Virol 1996; 49: 242–247.
  • 25
    Hino K, Yamaguchi Y, Fujiwara D, Katoh Y, Korenaga M, Okazaki M, et al. Hepatitis C virus quasispecies and response to interferon therapy in patients with chronic hepatitis C: a prospective study. J Viral Hepat 2000; 7: 36–42.
  • 26
    Kanazawa Y, Hayashi N, Mita E, Li T, Hagiwara H, Kasahara A, Fusamoto H, et al. Influence of viral quasispecies on effectiveness of interferon therapy in chronic hepatitis C patients. HEPATOLOGY 1994; 20: 1121–1130.
  • 27
    Koizumi K, Enomoto N, Kurosaki M, Murakami T, Izumi N, Marumo F, et al. Diversity of quasispecies in various disease stages of chronic hepatitis C virus infection and its significance in interferon treatment. HEPATOLOGY 1995; 22: 30–35.
  • 28
    Moribe T, Hayashi N, Kanazawa Y, Mita E, Fusamoto H, Negi M, et al. Hepatitis C viral complexity detected by single-strand conformation polymorphism and response to interferon therapy. Gastroenterology 1995; 108: 789–795.
  • 29
    Nagasaka A, Hige S, Tsunematsu I, Yoshida J, Sasaki Y, Matsushima T, et al. Changes in hepatitis C virus quasispecies and density populations in patients before and after interferon therapy. J Med Virol 1996; 50: 214–220.
  • 30
    Okada S, Akahane Y, Suzuki H, Okamoto H, Mishiro S. The degree of variability in the amino terminal region of the E2/NS1 protein of hepatitis C virus correlates with responsiveness to interferon therapy in viremic patients. HEPATOLOGY 1992; 16: 619–624.
  • 31
    Shindo M, Hamada K, Koya S, Arai K, Sokawa Y, Okuno T. The clinical significance of changes in genetic heterogeneity of the hypervariable region 1 in chronic hepatitis C with interferon therapy. HEPATOLOGY 1996; 24: 1018–1023.
  • 32
    Le Guen B, Squadrito G, Nalpas B, Berthelot P, Pol S, Brechot C. Hepatitis C virus genome complexity correlates with response to interferon therapy: a study in French patients with chronic hepatitis C. HEPATOLOGY 1997; 25: 1250–1254.
  • 33
    Lopez-Labrador FX, Ampurdanes S, Gimenez-Barcons M, Guilera M, Costa J, Jimenez MT, et al. Relationship of the genomic complexity of hepatitis C virus with liver disease severity and response to interferon in patients with chronic HCV genotype 1b infection. HEPATOLOGY 1999; 29: 897–903.
  • 34
    Nakazawa T, Kato N, Ohkoshi S, Shibuya A, Shimotohno K. Characterization of the 5′ noncoding and structural region of the hepatitis C virus genome from patients with non-A, non-B hepatitis responding differently to interferon treatment. J Hepatol 1994; 20: 623–629.
  • 35
    Sandres K, Dubois M, Pasquier C, Payen JL, Alric L, Duffaut M, et al. Genetic heterogeneity of hypervariable region 1 of the hepatitis C virus (HCV) genome and sensitivity of HCV to alpha interferon therapy. J Virol 2000; 74: 661–668.
  • 36
    Chambers TJ, Fan X, Droll DA, Hembrador E, Slater T, Nickells MW, et al. Quasispecies heterogeneity within the E1/E2 region as a pretreatment variable during pegylated interferon therapy of chronic hepatitis C virus infection. J Virol 2005; 79: 3071–3083.
  • 37
    Farci P, Strazzera R, Alter HJ, Farci S, Degioannis D, Coiana A, et al. Early changes in hepatitis C viral quasispecies during interferon therapy predict the therapeutic outcome. Proc Natl Acad Sci U S A 2002; 99: 3081–3086.
  • 38
    Sarrazin C, Bruckner M, Herrmann E, Rüster B, Bruch K, Roth WK, et al. Quasispecies heterogeneity of the carboxy-terminal part of the E2 gene including the PePHD and sensitivity of hepatitis C virus 1b isolates to antiviral therapy. Virology 2001; 289: 150–163.
  • 39
    Torres-Puente M, Cuevas JM, Jimenez-Hernandez N, Bracho MA, Garcia-Robles I, Wrobel B, et al. Genetic variability in hepatitis C virus and its role in antiviral treatment response. J Viral Hepatitis 2008; 15: 188–199.
  • 40
    Morishima C, Polyak SJ, Ray R, Doherty MC, Di Bisceglie AM, Malet PF, et al. Hepatitis C virus-specific immune responses and quasi-species variability at baseline are associated with nonresponse to antiviral therapy during advanced hepatitis C. J Infect Dis 2006; 193: 931–940.
  • 41
    Domingo E. Quasispecies theory in virology. J Virol 2002; 76: 463–465.
  • 42
    Biebricher CK, Eigen M. What is a quasispecies? Curr Top Microbiol 2006; 299: 1–31.
  • 43
    Bak P, Tang C, Wiesenfeld K. Self-organized criticality. Phys Rev 1998; 38: 364–374.
  • 44
    Wang WK, Lin SR, Lee CM, King CC, Chang SC. Dengue type 3 virus in plasma is a population of closely related genomes: quasispecies. J Virol 2002; 76: 4662–4665.
  • 45
    Jerzak G, Bernard KA, Kramer LD, Ebel GD. Genetic variation in West Nile virus from naturally infected mosquitoes and birds suggests quasispecies structure and strong purifying selection. J Gen Virol 2005; 86: 2175–2183.
View Full Article with Supporting Information (HTML) Get PDF (294K)